Form 4: Teladoc Health Director David B. Snow Jr. Reports Routine Equity Compensation Transactions

Teladoc Health Director David B. Snow Jr. reported the vesting of previously granted restricted stock units into common stock and the acquisition of a new grant of restricted stock units.

Summary

• David B. Snow Jr., a Director at Teladoc Health, Inc. (TDOC), reported changes in his beneficial ownership through a Form 4 filing.
• On May 21, 2025, 17,467 Restricted Stock Units (RSUs) that were granted on May 23, 2024, vested and converted into an equal number of common shares.
• Following this conversion, Mr. Snow directly holds 84,046 shares of Teladoc Health common stock.
• An additional 52,000 shares are indirectly held by the David B. Snow, Jr. Irrevocable Trust, dated December 12, 2012.
• On May 22, 2025, Mr. Snow acquired a new grant of 28,986 Restricted Stock Units.
• These newly acquired RSUs are scheduled to vest in full on the earlier of May 22, 2026, or the day immediately preceding Teladoc's 2026 annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The filing indicates routine insider transactions related to equity compensation, showing continued alignment of a director's interests with the company through RSU grants and vesting. This is generally a neutral to slightly positive signal as it reflects ongoing commitment, but it does not contain new financial performance data or significant strategic shifts.

Positives

• The vesting of RSUs indicates a long-term incentive structure for the director, aligning his financial interests with those of shareholders.
• The acquisition of new RSUs demonstrates continued commitment and future alignment of the director with the company's performance and long-term strategy.

Future Outlook

The new grant of Restricted Stock Units, with a vesting schedule extending into 2026, indicates a continued long-term incentive for the director, aligning his future compensation with the company's performance and strategic objectives.

Industry Context

This filing is a routine insider transaction report for a director of a telehealth company. It reflects standard equity compensation practices within the healthcare technology sector, aiming to align executive and director interests with long-term shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation is a common practice across publicly traded companies, including those in the healthcare technology sector like Teladoc Health.
• The vesting schedule (e.g., one year for the first grant, or two years/annual meeting for the second) is typical for director compensation, designed to encourage long-term commitment and performance.
• Similar compensation structures are observed in comparable companies within the digital health and telehealth space, such as Amwell (AMWL) or other health tech firms, where executive and director compensation often includes significant equity components to foster alignment with company growth.

Related Party Transactions

• The indirect ownership of 52,000 shares by the David B. Snow, Jr. Irrevocable Trust, for the benefit of the reporting person's children and with the spouse serving as trustee, constitutes a disclosed related party holding.

Stakeholder Impact

• Shareholders: The vesting and new grant of RSUs align the director's financial interests with long-term shareholder value, potentially fostering more diligent oversight and strategic decision-making.

Next Steps

• The 28,986 Restricted Stock Units are expected to vest on the earlier of May 22, 2026, or the day immediately preceding Teladoc Health's 2026 annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Teladoc Health, TDOC, Form 4, Insider Trading, Restricted Stock Units, RSU, Beneficial Ownership, Director, Equity Compensation, Stock Grant